LGND: Ligand Pharmaceuticals Incorporated Stock

by  •  • Comments Off on LGND: Ligand Pharmaceuticals Incorporated Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2,110.80
Enterprise Value ($M) 1,891.16
Book Value ($M) 841.18
Book Value / Share 44.52
Price / Book 2.51
NCAV ($M) 195.70
NCAV / Share 10.36
Price / NCAV 10.79

Profitability (mra)
Return on Invested Capital (ROIC) 0.05
Return on Assets (ROA) 0.06
Return on Equity (ROE) 0.07

Liquidity (mrq)
Quick Ratio 11.81
Current Ratio 12.49

Balance Sheet (mrq) ($M)
Current Assets 309.39
Assets 954.87
Liabilities 113.69
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
5 days ago 13G/A Janus Henderson Group Plc 5.50 -24.87
11-08 13G/A Goldman Sachs Group Inc 0.30 -95.57
11-01 13G/A Macquarie Group Ltd 4.86 -10.13
02-13 13G/A Vanguard Group Inc 10.76 1.81
01-22 13G/A BlackRock, Inc. 17.00 6.19

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange
2024-02-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-18 23,381 113,351 20.63
2024-11-15 25,707 86,976 29.56
2024-11-14 26,307 113,424 23.19
2024-11-13 40,866 196,974 20.75

(click for more detail)

Similar Companies
KROS – Keros Therapeutics, Inc. KYMR – Kymera Therapeutics, Inc.
LBPH – Longboard Pharmaceuticals, Inc. LNTH – Lantheus Holdings, Inc.
LRMR – Larimar Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io